Cravath Publishes Winter 2026 Issue of Alumni Journal
Joyce Law is the senior lead attorney in the Firm’s real estate practice. Ms. Law concentrates her practice on real estate development, acquisitions and dispositions, as well as real estate financing, including fund credit facilities and municipal financings, real estate fund work and leasing transactions. Ms. Law also regularly assists on the real estate aspects of various corporate mergers and acquisitions.
Ms. Law’s clients have included Martin Marietta Materials, The Walt Disney Company, IBM, INEOS, Thermo Fisher Scientific, Ashland, Valvoline, Ahold Delhaize, Kraft Foods, Bristol‑Myers Squibb, Unilever, Jones Apparel Group, Morgan Stanley, Westbrook Partners and The Dermot Company.
Ms. Law is from Rapid City, South Dakota. She received a Bachelor of Commerce with distinction from the University of Alberta in 1994 and a J.D. from Boston University in 1997. Ms. Law joined Cravath in 2001 and was named a senior attorney in 2015 and of counsel in 2025. Prior to joining Cravath, she was associated with a real estate developer in New York.
Ms. Law’s clients have included Martin Marietta Materials, The Walt Disney Company, IBM, INEOS, Thermo Fisher Scientific, Ashland, Valvoline, Ahold Delhaize, Kraft Foods, Bristol‑Myers Squibb, Unilever, Jones Apparel Group, Morgan Stanley, Westbrook Partners and The Dermot Company.
Ms. Law is from Rapid City, South Dakota. She received a Bachelor of Commerce with distinction from the University of Alberta in 1994 and a J.D. from Boston University in 1997. Ms. Law joined Cravath in 2001 and was named a senior attorney in 2015 and of counsel in 2025. Prior to joining Cravath, she was associated with a real estate developer in New York.
Education
-
J.D., 1997, Boston University School of Law
-
B.Comm., 1994, University of AlbertaDistinction
Admitted In
- New York
Deals & Cases
January 27, 2026
Siegfried’s Acquisition of Noramco, Purisys and Extractas
On January 27, 2026, Siegfried, a leading global Contract Development and Manufacturing Organization for the pharmaceutical industry, announced it has signed binding agreements with an affiliate of SK Capital Partners to acquire the drug substance business of the Noramco Group and Extractas Bioscience (“Extractas”). The acquired businesses include Noramco, Purisys and Extractas, three high-quality small molecules drug substances sites. Cravath is representing Siegfried in connection with the transaction.
Deals & Cases
December 09, 2025
Paramount’s $108.4 Billion All‑Cash Tender Offer to Acquire Warner Bros. Discovery, Inc.
On December 8, 2025, Paramount, a Skydance Corporation (“Paramount”), announced it has commenced an all-cash tender offer to acquire all of the outstanding shares of Warner Bros. Discovery, Inc. (“WBD”) for $30.00 per share in cash, equating to an enterprise value of $108.4 billion. Paramount’s proposed transaction is for the entirety of WBD, including the Global Networks segment. Cravath is representing Paramount in connection with the transaction.
Deals & Cases
November 18, 2025
Axalta’s $25 Billion Merger of Equals with AkzoNobel
On November 18, 2025, Axalta Coating Systems Ltd. (“Axalta”) and Akzo Nobel N.V. announced that they have entered into a definitive agreement to combine in an all‑stock merger of equals, creating a premier global coatings company with an enterprise value of approximately $25 billion. Cravath is representing Axalta in connection with the transaction.
Deals & Cases
November 17, 2025
Johnson & Johnson’s $3.05 Billion Acquisition of Halda Therapeutics OpCo, Inc.
On November 17, 2025, Johnson & Johnson announced it has entered into a definitive agreement to acquire Halda Therapeutics OpCo, Inc., a clinical‑stage biotechnology company with a proprietary Regulated Induced Proximity TArgeting Chimera (RIPTACTM) platform to develop oral, targeted therapies for multiple types of solid tumors, including prostate cancer, for $3.05 billion in cash. Cravath is representing Johnson & Johnson in connection with the transaction.
Deals & Cases
November 03, 2025
Kenvue’s $48.7 Billion Acquisition by Kimberly‑Clark
On November 3, 2025, Kenvue Inc. (“Kenvue”), a global consumer health leader, and Kimberly‑Clark Corporation (“Kimberly‑Clark”), a global personal care leader, announced an agreement under which Kimberly‑Clark will acquire all of the outstanding shares of Kenvue common stock in a cash and stock transaction that values Kenvue at an enterprise value of approximately $48.7 billion, based on the closing price of Kimberly‑Clark common stock on October 31, 2025. Under the terms of the agreement, which has been unanimously approved by each company’s Board of Directors, Kenvue shareholders will receive $3.50 per share in cash as well as 0.14625 Kimberly‑Clark shares for each Kenvue share held at closing. Upon closing of the transaction, current Kenvue shareholders are expected to own approximately 46% and current Kimberly‑Clark shareholders are expected to own approximately 54% of the combined company on a fully diluted basis. Cravath is representing Kenvue in connection with the transaction.
Firm News
November 20, 2025
Cravath Announces New Partners and Of Counsels
Cravath has elected the following new partners, who will become members of the Firm on January 1, 2026:
Joyce Law is the senior lead attorney in the Firm’s real estate practice. Ms. Law concentrates her practice on real estate development, acquisitions and dispositions, as well as real estate financing, including fund credit facilities and municipal financings, real estate fund work and leasing transactions. Ms. Law also regularly assists on the real estate aspects of various corporate mergers and acquisitions.
Ms. Law’s clients have included Martin Marietta Materials, The Walt Disney Company, IBM, INEOS, Thermo Fisher Scientific, Ashland, Valvoline, Ahold Delhaize, Kraft Foods, Bristol‑Myers Squibb, Unilever, Jones Apparel Group, Morgan Stanley, Westbrook Partners and The Dermot Company.
Ms. Law is from Rapid City, South Dakota. She received a Bachelor of Commerce with distinction from the University of Alberta in 1994 and a J.D. from Boston University in 1997. Ms. Law joined Cravath in 2001 and was named a senior attorney in 2015 and of counsel in 2025. Prior to joining Cravath, she was associated with a real estate developer in New York.
Ms. Law’s clients have included Martin Marietta Materials, The Walt Disney Company, IBM, INEOS, Thermo Fisher Scientific, Ashland, Valvoline, Ahold Delhaize, Kraft Foods, Bristol‑Myers Squibb, Unilever, Jones Apparel Group, Morgan Stanley, Westbrook Partners and The Dermot Company.
Ms. Law is from Rapid City, South Dakota. She received a Bachelor of Commerce with distinction from the University of Alberta in 1994 and a J.D. from Boston University in 1997. Ms. Law joined Cravath in 2001 and was named a senior attorney in 2015 and of counsel in 2025. Prior to joining Cravath, she was associated with a real estate developer in New York.
Education
-
J.D., 1997, Boston University School of Law
-
B.Comm., 1994, University of AlbertaDistinction
Admitted In
- New York
Deals & Cases
January 27, 2026
Siegfried’s Acquisition of Noramco, Purisys and Extractas
On January 27, 2026, Siegfried, a leading global Contract Development and Manufacturing Organization for the pharmaceutical industry, announced it has signed binding agreements with an affiliate of SK Capital Partners to acquire the drug substance business of the Noramco Group and Extractas Bioscience (“Extractas”). The acquired businesses include Noramco, Purisys and Extractas, three high-quality small molecules drug substances sites. Cravath is representing Siegfried in connection with the transaction.
Deals & Cases
December 09, 2025
Paramount’s $108.4 Billion All‑Cash Tender Offer to Acquire Warner Bros. Discovery, Inc.
On December 8, 2025, Paramount, a Skydance Corporation (“Paramount”), announced it has commenced an all-cash tender offer to acquire all of the outstanding shares of Warner Bros. Discovery, Inc. (“WBD”) for $30.00 per share in cash, equating to an enterprise value of $108.4 billion. Paramount’s proposed transaction is for the entirety of WBD, including the Global Networks segment. Cravath is representing Paramount in connection with the transaction.
Deals & Cases
November 18, 2025
Axalta’s $25 Billion Merger of Equals with AkzoNobel
On November 18, 2025, Axalta Coating Systems Ltd. (“Axalta”) and Akzo Nobel N.V. announced that they have entered into a definitive agreement to combine in an all‑stock merger of equals, creating a premier global coatings company with an enterprise value of approximately $25 billion. Cravath is representing Axalta in connection with the transaction.
Deals & Cases
November 17, 2025
Johnson & Johnson’s $3.05 Billion Acquisition of Halda Therapeutics OpCo, Inc.
On November 17, 2025, Johnson & Johnson announced it has entered into a definitive agreement to acquire Halda Therapeutics OpCo, Inc., a clinical‑stage biotechnology company with a proprietary Regulated Induced Proximity TArgeting Chimera (RIPTACTM) platform to develop oral, targeted therapies for multiple types of solid tumors, including prostate cancer, for $3.05 billion in cash. Cravath is representing Johnson & Johnson in connection with the transaction.
Deals & Cases
November 03, 2025
Kenvue’s $48.7 Billion Acquisition by Kimberly‑Clark
On November 3, 2025, Kenvue Inc. (“Kenvue”), a global consumer health leader, and Kimberly‑Clark Corporation (“Kimberly‑Clark”), a global personal care leader, announced an agreement under which Kimberly‑Clark will acquire all of the outstanding shares of Kenvue common stock in a cash and stock transaction that values Kenvue at an enterprise value of approximately $48.7 billion, based on the closing price of Kimberly‑Clark common stock on October 31, 2025. Under the terms of the agreement, which has been unanimously approved by each company’s Board of Directors, Kenvue shareholders will receive $3.50 per share in cash as well as 0.14625 Kimberly‑Clark shares for each Kenvue share held at closing. Upon closing of the transaction, current Kenvue shareholders are expected to own approximately 46% and current Kimberly‑Clark shareholders are expected to own approximately 54% of the combined company on a fully diluted basis. Cravath is representing Kenvue in connection with the transaction.
Firm News
November 20, 2025
Cravath Announces New Partners and Of Counsels
Cravath has elected the following new partners, who will become members of the Firm on January 1, 2026:
Cravath Bicentennial
Celebrating 200 years of partnership. In 2019, we celebrated our bicentennial. Our history mirrors that of our nation. Integral to our story is our culture.
Attorney Advertising. ©2026 Cravath, Swaine & Moore LLP.